癌症患者口服青霉素激发试验项目的安全性与有效性：一项多中心试点研究。
The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study.
作者信息
Trubiano Jason A, Smibert Olivia, Douglas Abby, Devchand Misha, Lambros Belinda, Holmes Natasha E, Chua Kyra Y, Phillips Elizabeth J, Slavin Monica A
机构信息
The National Centre for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Health, Melbourne, Australia.
出版信息
Open Forum Infect Dis. 2018 Nov 17;5(12):ofy306. doi: 10.1093/ofid/ofy306. eCollection 2018 Dec.
Antibiotic allergies are reported by up to 1 in 4 cancer patients, almost 50% of which are considered low risk and precede the cancer diagnosis. We demonstrate the successful and safe implementation of a pilot oral penicillin challenge program for cancer patients with low-risk penicillin allergies, increasing the use of penicillin and narrow-spectrum beta-lactams post-testing.
据报道，多达四分之一的癌症患者存在抗生素过敏，其中近50%被认为是低风险过敏，且发生在癌症诊断之前。我们证明了针对青霉素低风险过敏的癌症患者实施口服青霉素激发试验试点项目是成功且安全的，该项目增加了试验后青霉素和窄谱β-内酰胺类药物的使用。
Zotero 插件